The path to successful commercialization of cell and gene therapies: empowering patient advocates

Gerhard Bauer, Mohamed Abou-El-Enein, Alastair Kent, Brian Poole, Miguel Forte

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalCytotherapy
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Cell- and Tissue-Based Therapy
Genetic Therapy
Patient Advocacy

Keywords

  • affordability
  • cell and gene therapies
  • clinical trials commercialization
  • patient advocacy
  • regulation
  • reimbursement

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

The path to successful commercialization of cell and gene therapies : empowering patient advocates. / Bauer, Gerhard; Abou-El-Enein, Mohamed; Kent, Alastair; Poole, Brian; Forte, Miguel.

In: Cytotherapy, Vol. 19, No. 2, 01.02.2017, p. 293-298.

Research output: Contribution to journalArticle

Bauer, Gerhard ; Abou-El-Enein, Mohamed ; Kent, Alastair ; Poole, Brian ; Forte, Miguel. / The path to successful commercialization of cell and gene therapies : empowering patient advocates. In: Cytotherapy. 2017 ; Vol. 19, No. 2. pp. 293-298.
@article{1c41aa683fcf42369bf96578c6752347,
title = "The path to successful commercialization of cell and gene therapies: empowering patient advocates",
abstract = "Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.",
keywords = "affordability, cell and gene therapies, clinical trials commercialization, patient advocacy, regulation, reimbursement",
author = "Gerhard Bauer and Mohamed Abou-El-Enein and Alastair Kent and Brian Poole and Miguel Forte",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jcyt.2016.10.017",
language = "English (US)",
volume = "19",
pages = "293--298",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The path to successful commercialization of cell and gene therapies

T2 - empowering patient advocates

AU - Bauer, Gerhard

AU - Abou-El-Enein, Mohamed

AU - Kent, Alastair

AU - Poole, Brian

AU - Forte, Miguel

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.

AB - Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.

KW - affordability

KW - cell and gene therapies

KW - clinical trials commercialization

KW - patient advocacy

KW - regulation

KW - reimbursement

UR - http://www.scopus.com/inward/record.url?scp=85008147374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008147374&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2016.10.017

DO - 10.1016/j.jcyt.2016.10.017

M3 - Article

C2 - 27956199

AN - SCOPUS:85008147374

VL - 19

SP - 293

EP - 298

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 2

ER -